{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:31Z","timestamp":1790470231602,"version":"4.1.0"},"reference-count":80,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite considerable growth in our understanding of the heterogeneous biology and pathogenesis of acute myeloid leukemia (AML) in recent decades, for nearly forty years, little progress was gained in the realm of novel therapeutics. Since 2017, however, nine agents have been FDA-approved for patients with AML in both the upfront and relapsed\/refractory (R\/R) settings. Most of these compounds function as inhibitors of key cell cycle enzymatic pathways or mediators of leukemic proliferation and survival. They have been approved both as single agents and in combination with conventional or reduced-intensity conventional chemotherapeutics. In this article, we review the molecular landscape of de novo vs. R\/R AML and highlight the potential translational impact of defined molecular disease subsets. We also highlight several recent agents that have entered the therapeutic armamentarium and where they fit in the AML treatment landscape, with a focus on FLT3 inhibitors, IDH1 and IDH2 inhibitors, and venetoclax. Finally, we close with a survey of two promising novel agents under investigation that are poised to enter the mainstream clinical arena in the near future.<\/jats:p>","DOI":"10.3390\/cancers13184646","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T21:38:12Z","timestamp":1631828292000},"page":"4646","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"13","author":[{"given":"Khashayar","family":"Ahmadmehrabi","sequence":"first","affiliation":[{"name":"Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali R.","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aleem","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-5152","authenticated-orcid":false,"given":"Gregory W.","family":"Roloff","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute (2021). Surveillance, Epidemiology, and End Results (SEER) Program."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/PO.20.00387","article-title":"Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology","volume":"5","author":"Roloff","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1182\/bloodadvances.2018020206","article-title":"When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter","volume":"2","author":"Roloff","year":"2018","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/leu.2017.86","article-title":"The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia","volume":"31","author":"Eisfeld","year":"2017","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","article-title":"Evolution of acute myelogenous leukemia stem cell properties after treatment and progression","volume":"128","author":"Ho","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/leu.2015.141","article-title":"Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia","volume":"30","author":"Sood","year":"2015","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ferrell, P.B., Diggins, K.E., Polikowsky, H., Mohan, S.R., Seegmiller, A.C., and Irish, J.M. (2016). High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153207"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.32439","article-title":"Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis","volume":"125","author":"Zeidan","year":"2019","journal-title":"Cancer"},{"key":"ref_15","unstructured":"(2021, May 18). FDA Approves Venetoclax in Combination for AML in Adults, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults."},{"key":"ref_16","unstructured":"(2021, May 18). FDA Approves Glasdegib for AML in Adults Age 75 or Older or Who Have Comorbidities, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-glasdegib-aml-adults-age-75-or-older-or-who-have-comorbidities."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3324\/haematol.2018.192468","article-title":"Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: Results of a national survey","volume":"103","author":"Bories","year":"2018","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2017.56","article-title":"How good are we at predicting the fate of someone with acute myeloid leukaemia?","volume":"31","author":"Estey","year":"2017","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Palmieri, R., Paterno, G., De Bellis, E., Mercante, L., Buzzatti, E., Esposito, F., Del Principe, M.I., Maurillo, L., Buccisano, F., and Venditti, A. (2020). Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers, 12.","DOI":"10.3390\/cancers12010120"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2019","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41375-019-0704-5","article-title":"Recent drug approvals for newly diagnosed acute myeloid leukemia: Gifts or a Trojan horse?","volume":"34","author":"Estey","year":"2020","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41571-019-0180-x","article-title":"Registration studies\u2014When should patients be deemed ineligible for aggressive therapy?","volume":"16","author":"Cook","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune Escape of Relapsed AML Cells after Allogeneic Transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/leu.2009.143","article-title":"A robust xenotransplantation model for acute myeloid leukemia","volume":"23","author":"Sanchez","year":"2009","journal-title":"Leukemia"},{"key":"ref_33","first-page":"1","article-title":"Clonal competition within complex evolutionary hierarchies shapes AML over time","volume":"11","author":"Pietras","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation","volume":"13","author":"Mielcarek","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.bbmt.2011.07.012","article-title":"Genome-wide Profiling in AML Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation","volume":"17","author":"Waterhouse","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bbmt.2010.06.007","article-title":"Comparison of Cytogenetic Clonal Evolution Patterns following Allogeneic Hematopoietic Transplantation versus Conventional Treatment in Patients at Relapse of AML","volume":"16","author":"Bacher","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Jacoby, M.A., Duncavage, E.J., Chang, G.S., Miller, C.A., Shao, J., Elliott, K., Robinson, J., Fulton, R.S., Fronick, C.C., and O\u2019Laughlin, M. (2018). Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight, 3.","DOI":"10.1172\/jci.insight.98962"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kennedy, V.E., and Smith, C.C. (2020). FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.612880"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1517\/13543784.10.12.2117","article-title":"Protein kinase C inhibitors as novel anticancer drugs","volume":"10","author":"Jirousek","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","article-title":"Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C","volume":"19","author":"Propper","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1\u20132 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_48","unstructured":"(2021, June 15). FDA Approves Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutatation, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fped.2017.00248","article-title":"Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia","volume":"5","author":"Sexauer","year":"2017","journal-title":"Front. Pediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fped.2019.00463","article-title":"Targeted Therapies for Pediatric AML: Gaps and Perspective","volume":"7","author":"Lonetti","year":"2019","journal-title":"Front. Pediatr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2016","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/BLCTT.S236446","article-title":"Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence","volume":"11","author":"Stemer","year":"2021","journal-title":"Blood Lymphat. Cancer: Targets Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: A phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"Dinardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann Intern Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","article-title":"BCL-2 FAMILY: Regulators of Cell Death","volume":"16","author":"Chao","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of Population-Based Observational Studies With Randomized Trials in Oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2018","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrc991","article-title":"Inhibiting the p53\u2013MDM2 interaction: An important target for cancer therapy","volume":"3","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.3324\/haematol.2015.139717","article-title":"Acute myeloid leukemia patients\u2019 clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts","volume":"101","author":"Reis","year":"2016","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/fon-2020-0044","article-title":"MIRROS: A randomized, placebo-controlled, Phase III trial of cytarabine \u00b1 idasanutlin in relapsed or refractory acute myeloid leukemia","volume":"16","author":"Montesinos","year":"2020","journal-title":"Future Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"TPS7063","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7063","article-title":"MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia","volume":"37","author":"Montesinos","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_80","unstructured":"ANZCTR (2021, April 16). Trial Review. Available online: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=380788&isReview=true."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4646\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:37Z","timestamp":1760166037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":80,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13184646"],"URL":"https:\/\/doi.org\/10.3390\/cancers13184646","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}